|
|
Post by falconquest on Apr 8, 2019 19:19:35 GMT -5
Other posters have mentioned that Mannkind ought to do more PR than they currently do. With this in mind I read this article today and thought, this is a perfect model for good PR. I want to make full disclosure that I know nothing about the company involved, I have no financial interest in it, I am merely posting this as a good example of the type of PR that Mannkind could do. What are your thoughts?
|
|
|
|
Post by ktim on Apr 9, 2019 1:01:36 GMT -5
Other posters have mentioned that Mannkind ought to do more PR than they currently do. With this in mind I read this article today and thought, this is a perfect model for good PR. I want to make full disclosure that I know nothing about the company involved, I have no financial interest in it, I am merely posting this as a good example of the type of PR that Mannkind could do. What are your thoughts?
I'd be interested in views from people with actual experience in Pharma, but it has occurred to me at times that it seems companies that are still in trials rather than having an approved drug seem to actually have more leeway in what they can say and where. I suspect that the FDAs powers are less until such time as a drug is actually approved. Purely speculation on my part, but based on observation. |
|
|
|
Post by prosper on Apr 9, 2019 10:23:58 GMT -5
Other posters have mentioned that Mannkind ought to do more PR than they currently do. With this in mind I read this article today and thought, this is a perfect model for good PR. I want to make full disclosure that I know nothing about the company involved, I have no financial interest in it, I am merely posting this as a good example of the type of PR that Mannkind could do. What are your thoughts?
I'd be interested in views from people with actual experience in Pharma, but it has occurred to me at times that it seems companies that are still in trials rather than having an approved drug seem to actually have more leeway in what they can say and where. I suspect that the FDAs powers are less until such time as a drug is actually approved. Purely speculation on my part, but based on observation. You bring up an interesting point. I know there are NDA's for a lot of things in the pipeline and under internal research, but it may be worth the gamble to take advantage of the leeway you describe to throw out a lot of "what if" or "working on" PR. I am sure Mike knows what he legally can or cannot do, but perhaps he should fight allow more "speculation". A great salesman I knew years ago said, "I don't care what they say about me, just that they say it" Noise gets attention. |
|
|
|
Post by nesair on Apr 9, 2019 16:04:19 GMT -5
What we really need is a good social media campaign. You can run a good social media campaign for much less money than tv ads.
Start by finding popular diabetics to try the product. Become their sponsor and have them advertise on social media, blogs, twitter, instagram, etc. A good social media campaign can spread like wildfire. With how easy it is to share, people will do half the work for you. It's easy for people to click on links to find out more information. Once they are on your facebook /twitter/whatever page, they can look at your faqs, testimonials, etc and further engage with your ad.
|
|
|
|
Post by prcgorman2 on Apr 9, 2019 16:30:06 GMT -5
I'd say Conor Daly is a popular diabetic and to your point about a "good social media campaign" it would seem like Mannkind could work with Daly to bring his Wikipedia entry up-to-date.
|
|
